Catalyst Event
Novartis AG (NVS) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
4/28/2026, 12:00:00 AM
Announced on 2026-04-28 during its Q1 2026 earnings report that the FDA granted Breakthrough Therapy designation and priority review for ianalumab for the treatment of Sjögren's disease.
Korean Translation
2026년 4월 28일, 1분기 실적 발표를 통해 미국 FDA가 쇼그렌 증후군 치료제 이아날루맙(ianalumab)을 혁신치료제로 지정하고 우선심사 대상으로 선정했음을 발표함.
Related Recent Events
DICK'S Sporting Goods Inc (DKS) · Earnings Release
Q1 2026 earnings release is scheduled for 2026-05-27. Medium importance estimated as earnings releases for high-growth companies typically result in ≥5% price movement. Analysts forecast EPS of approximately $2.93 forecasted.
5/27/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
High importance estimated as earnings releases for major pharma often result in >10% price movement. Q1 2026 earnings release scheduled. Analysts forecast EPS of $0.87 and revenue of $11.35 billion forecasted.
5/6/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Eli Lilly reported Q1 2026 revenue of $19.8 billion (+56% YoY) and non-GAAP EPS of $8.55, beating estimates. The company raised its full-year 2026 revenue guidance to $82-$85 billion, driven by strong sales of Mounjaro and Zepbound. This significant growth and guidance raise is estimated to result in a >10% price impact.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
The U.S. FDA proposed removing tirzepatide, the active ingredient in Mounjaro and Zepbound, from the bulk drug substances list on 2026-04-30, restricting compounded versions. This regulatory protection of market share is estimated to result in a >10% price impact.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Reported Q1 2026 financial results, posting a GAAP Loss per Share of $1.72, which included a $3.62 per share charge from the acquisition of Cidara Therapeutics. Revenue grew 5% to $16.3 billion. The company raised its full-year 2026 guidance; high importance due to guidance raise and acquisition impact, market reaction expected.
4/30/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
High importance estimated as this regulatory change protects core revenue from competition, likely impacting price by >10%. The U.S. FDA proposed to exclude the active ingredients in key Novo Nordisk GLP-1 drugs from the bulk compounding list.
4/30/2026, 12:00:00 AM